CA2299397A1 - Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine - Google Patents

Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine Download PDF

Info

Publication number
CA2299397A1
CA2299397A1 CA002299397A CA2299397A CA2299397A1 CA 2299397 A1 CA2299397 A1 CA 2299397A1 CA 002299397 A CA002299397 A CA 002299397A CA 2299397 A CA2299397 A CA 2299397A CA 2299397 A1 CA2299397 A1 CA 2299397A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
statin
pharmaceutical composition
kit
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002299397A
Other languages
English (en)
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Randy Ranjee Ramharack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2299397A1 publication Critical patent/CA2299397A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique renfermant un inhibiteur de lipoprotéine (a) et une statine, qui a un effet inhibiteur sur la HMG-CoA réductase. Ce type de composition est utile pour le traitement des maladies vasculaires.
CA002299397A 1997-12-12 1998-11-04 Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine Abandoned CA2299397A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6943297P 1997-12-12 1997-12-12
US60/069,432 1997-12-12
PCT/US1998/023480 WO1999030706A1 (fr) 1997-12-12 1998-11-04 Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine

Publications (1)

Publication Number Publication Date
CA2299397A1 true CA2299397A1 (fr) 1999-06-24

Family

ID=22088939

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002299397A Abandoned CA2299397A1 (fr) 1997-12-12 1998-11-04 Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine

Country Status (14)

Country Link
EP (1) EP1037623A1 (fr)
JP (1) JP2003524582A (fr)
KR (1) KR20010033017A (fr)
AU (2) AU1306099A (fr)
BR (1) BR9813539A (fr)
CA (1) CA2299397A1 (fr)
HU (1) HUP0100349A3 (fr)
IL (1) IL134364A0 (fr)
IS (1) IS5385A (fr)
NO (1) NO20002965D0 (fr)
NZ (1) NZ502874A (fr)
PL (1) PL343851A1 (fr)
WO (1) WO1999030706A1 (fr)
ZA (1) ZA9811349B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
EP1076091A1 (fr) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Composé ou composition pharmaceutique pour la prévention et/ou le traitement d'ischémie cardiaque, de maladies vasculaires périphériques, de tumeurs et de plaies
EP1246638B2 (fr) * 2000-01-10 2014-07-30 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et d'agonistes de ces dernieres pour traiter l'hypertriglyceridemie
EP1275388A4 (fr) * 2000-02-10 2003-11-26 Takeda Chemical Industries Ltd Inhibiteurs de tnf-alpha

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016467A1 (fr) * 1989-06-05 1990-12-05 Martin Eisman Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase
WO1993013801A1 (fr) * 1992-01-17 1993-07-22 The Procter & Gamble Company Traitement de l'arteriosclerose
AU4275793A (en) * 1992-02-25 1993-09-13 Warner-Lambert Company Cytoprotective compositions containing pyruvate and antioxidants
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
EP0904082A4 (fr) * 1996-04-17 2001-09-26 Merck & Co Inc Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
NO20002965L (no) 2000-06-09
HUP0100349A2 (hu) 2001-07-30
EP1037623A1 (fr) 2000-09-27
WO1999030706A1 (fr) 1999-06-24
HUP0100349A3 (en) 2002-02-28
ZA9811349B (en) 1999-06-14
IL134364A0 (en) 2001-04-30
PL343851A1 (en) 2001-09-10
JP2003524582A (ja) 2003-08-19
NZ502874A (en) 2004-03-26
KR20010033017A (ko) 2001-04-25
AU1306099A (en) 1999-07-05
BR9813539A (pt) 2000-10-10
AU2003244047A1 (en) 2003-09-25
NO20002965D0 (no) 2000-06-09
IS5385A (is) 2000-02-25

Similar Documents

Publication Publication Date Title
AP1207A (en) Combination therapy.
US6455574B1 (en) Therapeutic combination
EP1045691B1 (fr) Combinaisons de statine-carboxyalkylether
CN1373753A (zh) 氨氮地平和阿托伐他汀的公共盐
US8557835B2 (en) Statin-carboxyalkylether combinations
US20040248948A1 (en) Combination therapy
AU1306099A (en) Antihyperlipidemic statin-lp(a) inhibitor combinations
US20020103252A1 (en) Statin-carboxyalkylether combinations
EP1280522B1 (fr) Combinaison de carboxyalkylethers avec des agents antihypertenseurs et leur utilisation
US20040092574A1 (en) Statin-Lp(a) inhibitor combinations
MXPA00002105A (en) Antihyperlipidemic statin-lp(a) inhibitor combinations
EP1481962A1 (fr) Nouveau carboxyéthylether reduisant la cholesterolémie
MXPA00002104A (en) Carton with panel locking means
US20030225123A1 (en) Antihypertensive agents and use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued